Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. (Nasdaq: ALLR) on April 12, 2022. The Company is an emerging growth company incorporated in Delaware. The report details a material definitive agreement with Novartis Pharma AG and a subsequent restatement of historical financial statements.
Key Financial Metrics and Obligations
The filing discloses the re-issuance of a Convertible Promissory Note to Novartis Pharma AG in the principal amount of $1,000,000. The Note accrues interest effective from April 6, 2018. The filing does not provide current revenue, profit, cash flow, or liquidity metrics, as it focuses on a specific contractual amendment and accounting correction.
Material Changes and Restatement
The Company announced a material change regarding its historical financial reporting. Management concluded that:
- The $1,000,000 Convertible Promissory Note should have been recorded as a liability in 2018 but was not.
- The valuation allowance on deferred tax assets relating to net operating losses was understated in 2019 and 2020.
Consequently, the Company will restate its audited consolidated financial statements for the fiscal years ended December 31, 2019, and 2020. These periods are designated as the "Non-Reliance Periods."
Management Commentary, Risks, and Internal Controls
Management identified an additional material weakness in internal control over financial reporting during the Non-Reliance Periods. The Board of Directors concluded that previously issued financial statements included in the Company's Form S-1 registration statement should no longer be relied upon. Remediation plans include enhancing processes for evaluating complex accounting standards, providing increased access to accounting literature, and improving communication with third-party professionals. The Company intends to file a Post-Effective Amendment No. 1 to its Form S-1 to reflect the restatement.
Investor Verification Checklist
- Verify the terms of the First Amendment to the License Agreement and the Convertible Promissory Note filed as Exhibits 10.1 and 10.2.
- Monitor the upcoming Post-Effective Amendment No. 1 to the Form S-1 for the restated financial figures for 2019 and 2020.
- Assess the impact of the understated valuation allowance on deferred tax assets on the Company's net income and equity.
- Review the Company's progress in remediating the identified material weakness in internal controls.